Pharma BD Deal Intelligence

AstraZeneca PLC / Bristol-Myers Squibb Company / Amylin diabetes alliance

2012 · Co-Development · $3.5B · Complete

Announcement Sentiment

Negative

Following BMS acquisition of Amylin, AstraZeneca paid BMS $3.4B cash to enter 50/50 profit share on the Amylin GLP-1 portfolio (Byetta, Bydureon). Optional $135M for equal governance rights. Expanded the existing BMS-AZ diabetes alliance.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Assets Stalled

Assessment window: 10yr post-close.

Key facts

Announced Jun 29, 2012
Closed Aug 09, 2012
Deal value $3.5B
Deal type Co-Development
Therapeutic area Type 2 diabetes, severe lipodystrophy
Indications Type 2 diabetes, severe lipodystrophy
Key assets Byetta (exenatide), Bydureon (exenatide ER), metreleptin
Mechanism GLP-1 receptor agonists; leptin analog

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals